why choose us

First received: June 29, 2023

Clinical Trial: SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Study Status: Completed

Recruit Status: RECRUITING

Condition: Non-small Cell Lung Cancer

Study Type: OBSERVATIONAL


Official Title: SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

Brief Summary: The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors.It is necessary to collect clinical data points and treatment outcomes in order to demonstrate clinical validity for longitudinal monitoring with ctDNA and correlation of ctDNA dynamics with therapeutic response, as evaluated by standard methods, including RECIST 1.1 and CT scan…

Read more